Welcome to our dedicated page for Inozyme Pharma SEC filings (Ticker: INZY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The INZY SEC filings page on Stock Titan compiles U.S. Securities and Exchange Commission documents historically filed by Inozyme Pharma, Inc., which traded on the Nasdaq Global Select Market under the symbol INZY before its acquisition by BioMarin Pharmaceutical Inc. These filings trace Inozyme’s life cycle as a public company, from its status as a clinical-stage biopharmaceutical issuer through its change of control, delisting, and deregistration.
Key transaction-related filings include a Form 8-K dated July 1, 2025, reporting the completion of BioMarin’s acquisition of Inozyme pursuant to an Agreement and Plan of Merger. This filing explains that a BioMarin subsidiary merged with and into Inozyme, with Inozyme continuing as the surviving corporation and becoming a wholly owned subsidiary of BioMarin. The same Form 8-K describes the tender offer at $4.00 per share in cash and the subsequent conversion of remaining shares into the right to receive the same consideration.
For trading status, a Form 25 filed on July 1, 2025, by Nasdaq Stock Market LLC documents the removal of Inozyme’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. A Form 15 filed on July 11, 2025, then certifies the termination of registration of Inozyme’s common stock under Section 12(g) and the suspension of its duty to file periodic reports under Sections 13 and 15(d). Together, these filings confirm that INZY is a delisted and deregistered security.
Earlier periodic and current reports, such as Forms 10-K, 10-Q, and 8-K referenced in Inozyme’s press releases, provide additional context on the company’s clinical-stage operations, including its focus on the PPi-Adenosine Pathway, development of INZ-701 for ENPP1 and ABCC6 Deficiencies, and financial position prior to the acquisition. While those documents are accessed directly through the SEC’s EDGAR system, this page highlights the most material items for understanding INZY’s regulatory history.
Stock Titan enhances access to these filings with AI-powered summaries that explain the purpose and implications of each document in plain language. Users can quickly see how specific Forms 8-K relate to the merger and delisting, how the Form 25 and Form 15 altered Inozyme’s reporting obligations, and how the company’s disclosures fit into the broader narrative of its transition from an independent public issuer to a BioMarin subsidiary. This makes the INZY filings page a practical resource for anyone researching historical corporate actions, listing status changes, and the regulatory record associated with Inozyme Pharma’s former public listing.
Inozyme Pharma, Inc. (INZY) has submitted a Form 25 to the SEC, signaling the removal of its common stock from listing and registration on the Nasdaq Stock Market under Section 12(b) of the Exchange Act.
The document, signed by Nasdaq AVP Tara Petta on 2025-07-01, states that the exchange has met all procedural requirements of Rule 12d2-2 for striking the security. The filing covers only the company’s common stock and does not disclose the reason for the delisting—whether involuntary (e.g., non-compliance) or voluntary (e.g., merger, alternate listing).
After effectiveness, trading in INZY shares on Nasdaq will cease and the Section 12(b) registration will be withdrawn 10 days later, materially affecting share liquidity, index eligibility, and disclosure obligations. Investors should watch subsequent SEC filings or company announcements for context on trading venue migration (such as OTC) and any strategic ramifications.
FAQ
What is the current stock price of Inozyme Pharma (INZY)?
What is the market cap of Inozyme Pharma (INZY)?
